Samsung BioLogics Eyes Global Leadership Via Korean IPO
This article was originally published in PharmAsia News
In its ongoing efforts to become the world's top biopharmaceutical manufacturing company, Samsung BioLogics has decided to launch an initial public offering in the benchmark Korean stock market this year amid weak biotech sentiment in the US. Proceeds from the IPO, poised to be one of the biggest domestic IPOs, will be used for further expansion of its manufacturing facilities.
Register for our free email digests: